GLP-1 Detection Service

Glucagon-like peptide 1 (GLP-1) is a peptide hormone produced by proglucagon. As an incretin hormone, GLP-1 can promote insulin secretion and inhibit glucagon secretion. GLP-1 has been used in the treatment of type 2 diabetes mellitus due to its effective hypoglycemic effect. GLP-1 is closely related to glycometabolism in the body and can be used as a biomarker for diseases related to glucose metabolism such as diabetes mellitus. Creative BioMart Biomarker offers sensitive testing service both for total GLP-1 and the biologically active forms of GLP-1, ensuring providing accurate and reliable test results.

Introduction

GLP-1 is a peptide hormone composed of 30 amino acids, which is generally obtained by cleavage of its precursor protein, preproglucagon. The proglucagon gene is expressed in cells of multiple organs, including α cells in the islets, enteroendocrine L cells, and certain neuronal cells in the isolated nucleus of the brainstem. Proglucagon undergoes tissue-specific post-translational division in these cells to produce glucagon, GLP-1 and GLP-2, in which glucagon is produced in islets, and GLP is produced in the intestine. GLP-1 is generally produced by the intestine and secreted into the circulatory system, acting on pancreatic β-cell receptors in response to elevated glucose caused by eating, ultimately promoting an increase in glucose-stimulated insulin secretion (GSIS). The binding of GLP-1 to its receptor GLP-1R can mediate the energy metabolism process of the human body. GLP-1R is generally located in peripheral tissues (such as pancreatic cells and vagus nerve afferent fibers) and the central nervous system.GLP-1-based treatments can promote autophagy in patients with cardiac metabolism. The imbalance of autophagy in the homeostasis is related to abnormal metabolism, and then to abnormal physical conditions such as obesity, insulin resistance, diabetes, and atherosclerosis. The treatment based on GLP-1 can positively affect the autophagy of perivascular adipose tissue, and treat diseases through metabolic regulation. In addition to the regulation of insulin and glucagon, the role of GLP-1 in the body includes reducing hepatic glucose output through gluconeogenesis inhibition, reducing insulin resistance in skeletal muscle, slowing gastric emptying, and stimulating stimulate cell proliferation, and increasing thermogenesis. GLP-1 can be used not only in the study of treatment strategies for diseases such as diabetes and obesity, but also as a biomarker in the process of treatment research.

Actions of GLP-1 in target tissues.
Figure 1. Actions of GLP-1 in target tissues. (Deborah, 2017)

Application of GLP-1 Detection

Plasma and serum GLP-1 levels can be studied as a biomarker in researches related to obesity and diabetes mellitus.

Our Advantages

  • Guarantee high accuracy and sensitivity for GLP-1 detection
  • Ensure high repeatability of GLP-1 detection
  • Short turn-around time of detection service
  • Competitive price in the market of GLP-1 detection services
  • Multiple technology platforms for GLP-1 test services (ELISA, ECL, CLIA, etc.)
  • Accept a wide range of sample types (plasma, serum, cell culture supernatants, etc.)

Workflow of GLP-1 Detection at Creative BioMart Biomarker

Creative BioMart Biomarker strictly controls each specific experimental step in the GLP-1 detection procedure to ensure accurately quantify the level of GLP-1 in each sample.

Workflow

At Creative BioMart Biomarker, we offer GLP-1 detection service which include several technical methods, you can communicate with our experts according to your research needs, and we will determine the final detection technical scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.

References:

  1. Habener, J.F.; Stanojevic, V. Pancreas and not gut mediates the GLP-1-induced glucoincretin effect. Cell Metabolism. 2017, 25(4): 757-758.
  2. Deborah, H. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectrum. 2017, 30(3): 202-210.
  3. Costantino, S.; Paneni, F. GLP-1-based therapies to boost autophagy in cardiometabolic patients: from experimental evidence to clinical trials. Vascular Pharmacology. 2019, 115:64-68.
  4. González-García, I.; et al. Glucagon, GLP-1 and Thermogenesis. International Journal of Molecular Sciences. 2019, 20(14): 1-16.

Menu

Contact Us

Subscribe

Enter your email here to subscribe